Antibody discovery and development is the process of creating, selecting and characterizing an antibody. Antibody discovery begins in one of two ways, either in vivo by injecting the antigen of interest into a host allowing the immune system to naturally develop a wide variety of antibodies from which the most effective binding antibody is selected, or in vitro by using a phage display library approach.
Comprehensive antibody discovery platform
Antibody discovery can be challenging depending on the nature and complexity of the target of interest and the application for which it is being developed. Our comprehensive antibody discovery platform gives us the ability to tackle and successfully develop antibodies against even the most challenging of targets.
- B Cell Cloning
- Next Generation Sequencing (NGS)
- Phage Display
Our in-house development efforts are focused on generating antibodies that combine the high affinity and specificity of rabbit immune system with the consistency of the recombinant format. This approach creates recombinant rabbit monoclonal antibodies (recombinant RabMAbs®) that are specific and very sensitive to the target molecule of interest. Being recombinant means that the resulting antibody can be repeatedly manufactured in vitro ensuring lot-to-lot consistency and enabling long-term security of supply. In addition this recombinant format means that they can be genetically engineered to add epitope or molecular tags and other sequences to match applications.
- High specificity and affinity
- Batch-to-batch consistency
- Sustainable long-term supply
Browse our range of recombinant antibodies on abcam.com
We have delivered custom-engineered antibodies using proprietary RabMAb technology for over 2000 collaborative projects and have over 20,000 recombinant RabMAbs in our portfolio.
Antibody screening cascades to select fit-for-purpose antibodies
To find the best binders early, antibody discovery requires an individualized assay cascade designed for the target of interest. Broadly consisting of a primary screen, secondary screen, and application-specific testing, the more extensive and well-designed the cascade, the better the chance of finding and developing the best antibody. At each step we apply more precise tests, but we always ask: is this the right test, or is there something else we should do? We are constantly innovating and finding better ways to predict performance in the final application.